CervoMed FY2025 EPS Forecast Reduced by HC Wainwright

CervoMed Inc. (NASDAQ:CRVO) – HC Wainwright cut their FY2025 earnings per share estimates for shares of CervoMed in a report issued on Monday, November 10th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($2.84) for the year, down from their previous forecast of ($2.60). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.64) EPS and FY2026 earnings at ($2.89) EPS.

A number of other research firms also recently issued reports on CRVO. Roth Capital set a $20.00 price objective on shares of CervoMed and gave the company a “buy” rating in a research note on Friday, October 17th. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price target on shares of CervoMed in a report on Tuesday. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of CervoMed in a research note on Monday, August 11th. Zacks Research lowered CervoMed from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CervoMed in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.86.

CervoMed Price Performance

Shares of CervoMed stock opened at $6.97 on Wednesday. The stock has a market cap of $64.49 million, a price-to-earnings ratio of -2.67 and a beta of -0.89. The firm’s 50-day moving average is $8.06 and its two-hundred day moving average is $8.18. CervoMed has a 1 year low of $1.80 and a 1 year high of $16.94.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.43 million. CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.

Institutional Trading of CervoMed

Several large investors have recently bought and sold shares of CRVO. Rhumbline Advisers raised its holdings in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after buying an additional 1,526 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of CervoMed in the 2nd quarter valued at $76,000. Thompson Davis & CO. Inc. acquired a new position in shares of CervoMed in the 2nd quarter valued at $88,000. GSA Capital Partners LLP purchased a new position in CervoMed in the 3rd quarter worth $91,000. Finally, HighTower Advisors LLC acquired a new stake in CervoMed during the 1st quarter worth about $104,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.